We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical executives from the nation’s leading firms are urging Congressional leaders to pass a Republican-led tax reform that would allow companies to pay lower taxes. Read More
A California lawmaker introduced a bill that would prohibit pharmaceutical companies from issuing certain prescription drug discounts or coupons to consumers in the state. Read More
Pfizer is the latest drugmaker to reveal that it received subpoenas requesting information on the company’s relationship with nonprofit organizations that curb the prices of costly drugs through financial assistance programs. Read More
The EMA’s Committee for Medicinal Products for Human Use recommended approvals for six drugs within the EU to treat a range of conditions from an endocrine disease to nausea. Read More
Sovereign Pharmaceuticals’ Texas facility received a Form 483 after an inspection in November found numerous problems in the facility, including the building’s construction. Read More
The FDA will have to create a task force to identify regulations to repeal or modify under an executive order signed by President Trump last week. Read More
The U.S. solicitor general and several generics makers have filed U.S. Supreme Court briefs in support of reversing a Federal Circuit ruling that orders sponsors to wait six months after an FDA approval to launch a biosimilar. Read More